Phase 3 N=1,457 Methotrexate-Inadequate Response Study
Rheumatoid Arthritis (RA)
Primary: Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169 — 527; 514 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=339 Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (Week 12). — -0.91; -0.97; -0.19 percentage of Glycosylated Hemoglobin
Phase 3 N=1,374 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
Meningococcal Meningitis · Measles · Mumps
Primary: Percentage of Participants With at Least One Solicited Injection Site Reaction or Systemic Reaction Following Vaccination. — 52; NA; 37; NA Percentage of participants
Phase 3 N=62 Methotrexate - Inadequate Response Device Sub-Study
Rheumatoid Arthritis (RA)
Primary: Number of Participants With Death, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs…
Phase 3 N=312 Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (Week 12). — -0.60; -0.66; 0.34 percentage of Glycosylated Hemoglobin
Phase 3 N=273 Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa
Cystic Fibrosis
Primary: Relative Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28 — 8.35; 0.55 percent change in FEV1 percent predicted — p=0.0001
Phase 3 N=604 Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
Osteoporosis
Primary: Change of Cross-linked N-telopeptide of Type I Collagen (NTx) Level Assessed as Standardized Area Under the Curve From Screening to Month 12 in the Intent-to-Treat…
Phase 3 N=606 A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia
Erectile Dysfunction · Benign Prostatic Hyperplasia
Primary: Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (5 mg) — -6.1; -3.8 units on a scale — p=<0.001
Phase 3 N=35 Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
Hypertension
Primary: Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP). — -2.86 Millimeters of Mercury (mm Hg)
Phase 3 N=349 TAXUS PERSEUS Small Vessel
Coronary Artery Disease
Primary: In-stent Late Loss Measured by Quantitative Coronary Angiography (QCA) — 0.38; 0.80 millimeter — p=<0.0001
Phase 3 N=1,262 TAXUS PERSEUS Workhorse
Coronary Artery Disease
Primary: Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction…
Phase 3 N=7 Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
Chronic Gout Refractory to Conventional Therapy
Primary: Adverse Event Profile — 7; 2 Number of participants
Phase 3 N=262 Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Participants Who Discontinued From the Study Due to Any Reason During the Core Phase of the Study — 11; 10 Participants
Phase 3 N=2,743 A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
Heart Failure
Primary: Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date — 249; 356…
Phase 3 N=157 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo
HC-BPPV
Primary: Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo: A Randomized Clinical Trial — 38; 33; 17 participants